Wed, Jun 11, 8:07 PM (32 days ago)
AEON Biopharma, Inc. (AEON, NYSE American) filed an amendment (Form 10-Q/A) to its Q1 2025 quarterly report. The amendment, dated May 7, 2025, is an exhibit-only filing. The sole purpose is to supplement Exhibit 3.2.1, the Company’s Amendment to its Amended and Restated Bylaws, which was inadvertently omitted in the original filing. No changes were made to the original financial or other information. The amendment does not reflect events occurring after the original filing date. The Company remains a smaller reporting company and is not a shell company. As of May 7, 2025, there were 11,305,367 shares of Class A common stock outstanding. The amendment includes certifications pursuant to the Sarbanes-Oxley Act and XBRL filings. The Company has filed all required reports and submitted electronically every Interactive Data File required. The amendment does not modify, amend, or update any financial or other information contained in the original filing.